Granta-452Homo sapiens (Human)Cancer cell line

Granta-452 is a human B-cell lymphoma cell line characterized by concurrent rearrangements of MYC and BCL2, placing it within the category of double-hit B-cell lymphomas. This cell line is derived from a patient with B-cell acute leukemia and has been used in research to study the molecular mechanisms underlying aggressive lymphomas. The cell line exhibits a complex karyotype with multiple chromosomal abnormalities, including deletions and translocations that are commonly associated with high-grade B-cell malignancies. Granta-452 is part of a panel of cell lines utilized for in vitro modeling of double-hit lymphomas, providing insights into the pathogenesis and potential therapeutic targets for these aggressive cancers. Its genetic profile makes it a valuable tool for investigating the role of MYC and BCL2 in lymphomagenesis and for developing targeted therapies.